DDInter1387 DDInter1676
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Panobinostat {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon beta-1a
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Ivabradine
Panobinostat {u} may lead to a major life threatening interaction when taken with {v} Posaconazole
Panobinostat {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Flurbiprofen
Panobinostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac
Panobinostat may lead to a major life threatening interaction when taken with Ivabradine
Panobinostat may lead to a major life threatening interaction when taken with Posaconazole
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Panobinostat may lead to a major life threatening interaction when taken with Flurbiprofen